CD46 and prostate cancer: The CD46-ADC approach has also shown efficacy in metastatic castration-resistant prostate cancer, utilizing a tubulin inhibitor conjugated as the ADC added to a macropinocytosing anti-CD46 antibody (Ab) [65].